Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia

Item

http://www.wikidata.org/entity/Q35951606

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Self-administered, subcutaneou ...... h chronic lymphocytic leukemia

@ast

Self-administered, subcutaneou ...... h chronic lymphocytic leukemia

@en

type

Item

label

Self-administered, subcutaneou ...... h chronic lymphocytic leukemia

@ast

Self-administered, subcutaneou ...... h chronic lymphocytic leukemia

@en

prefLabel

Self-administered, subcutaneou ...... h chronic lymphocytic leukemia

@ast

Self-administered, subcutaneou ...... h chronic lymphocytic leukemia

@en

P1476

Self-administered, subcutaneou ...... h chronic lymphocytic leukemia

@en

P2093

Andrew W Greaves

http://www.w3.org/2001/XMLSchema#string

CLL Research Consortium

http://www.w3.org/2001/XMLSchema#string

Donna Neuberg

http://www.w3.org/2001/XMLSchema#string

Jennifer R Brown

http://www.w3.org/2001/XMLSchema#string

John G Gribben

http://www.w3.org/2001/XMLSchema#string

Laura Z Rassenti

http://www.w3.org/2001/XMLSchema#string

Mary Browning

http://www.w3.org/2001/XMLSchema#string

Susan M O'Brien

http://www.w3.org/2001/XMLSchema#string

Thomas J Kipps

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

Novel immune-based treatment strategies for chronic lymphocytic leukemia.

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

Pharmacokinetics of CAMPATH-1H: assay development and validation.

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

P304

116-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25379

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

William G Wierda

Michael J. Keating

P577

2010-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46096299

http://www.w3.org/2001/XMLSchema#string

P698

20806349

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte

P932

4535917

http://www.w3.org/2001/XMLSchema#string